MedTrace Logo

Study of SRX246 Capsules in Healthy Adult Volunteers

NCT00910455 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 49

Last updated 2010-03-17

No results posted yet for this study

Summary

This is the first study of SRX246 in humans, and is being conducted to begin to establish a safety profile of orally administered SRX246.

Conditions

  • Healthy

Interventions

DRUG

SRX246

single oral dose of SRX246 capsule

DRUG

Placebo

Single oral dose of placebo capsule

Sponsors & Collaborators

  • Azevan Pharmaceuticals

    lead INDUSTRY

Principal Investigators

  • Benno G Roesch, MD · Advanced Biomedical Research

Study Design

Allocation
RANDOMIZED
Masking
QUADRUPLE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2009-05-31
Primary Completion
2009-09-30
Completion
2009-09-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00910455 on ClinicalTrials.gov